Tag: Andrew Gwynne

The below Parliamentary question was asked by Andrew Gwynne on 2015-12-17.

To ask the Secretary of State for Health, if he will maintain patient access to technologies considered through commissioning through evaluation programmes during that evaluation.

George Freeman

There are two main phases for any treatments entered into NHS England’s Commissioning through Evaluation (CtE) programme.

During the first phase, an agreed number of patients are recruited to the scheme within just a few participating centres across England. This enables patients to benefit from the skills and expertise in each centre, within an evaluation programme, whilst detailed clinical and patient experience data are collected.

Once the total number of patients have been treated, the scheme enters an analysis phase. Whilst any patients already treated under the scheme will continue to receive appropriate follow up care, no new patients will be funded by NHS England during the analysis phase.

This ensures that NHS England directs the majority of public funds to evidence based care and also means that dedicated CtE programme funding can then be redirected to support patient recruitment in another area of specialised care where further evaluation data is needed.

This represents a continuation of NHS England’s published policy position for the treatment concerned (i.e. that the treatment is not routinely commissioned by the National Health Service).

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-14.

To ask the Secretary of State for Work and Pensions, what projects his Department plans to fund through the £40 million allocated to the Health and Work Innovation Fund.

Priti Patel

The Work and Health innovation fund will be used to build an evidence base for what works to improve employment and health outcomes.

This evidence base will enable the Work and Health Unit to develop proposals for Longer Term reform across Work and health Systems The Unit is currently working with partners including NHS England to develop these proposals.

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-27.

To ask the Secretary of State for Defence, whether his Department has an insurance policy in place for civilian residents on the land around RAF Northolt to cover possible damage to their properties.

Mark Lancaster

The Ministry of Defence does not purchase insurance policies in the UK but accepts its own risks and acts as its own insurer.

The below Parliamentary question was asked by Andrew Gwynne on 2016-01-28.

To ask the Secretary of State for Health, what the budget was for the Rare and Imported Pathogens Laboratory in each of the last five years.

Jane Ellison

Public Health England (PHE) was formed on 1 April 2013; below are budgets for the Rare and Imported Pathogens Laboratory (RIPL) for each year since PHE’s formation. The RIPL was previously part of the Health Protection Agency, whose functions transferred to PHE.

2013/14 (Actual)	2014/15 (Actual)	2015/16 (Budget)
£3,491,300	£3,667,600	£3,465,300

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-02.

To ask the Secretary of State for Health, whether the Prime Minister has seen a draft childhood obesity strategy document.

Jane Ellison

As part of the development of the Childhood Obesity Strategy, the Secretary of State has regular meetings to discuss its content. The Childhood Obesity Strategy will be published shortly.

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-05.

To ask the Secretary of State for Defence, how much his Department has paid out in compensation to (a) internal and (b) external claimants in each year since 2010.

Mark Lancaster

The amounts paid as a result of claims brought by internal and external claimants including claimants’ legal costs from Financial Year (FY) 2010-11 to FY2013-14 are shown below. The costs for FY 2014-15 are being finalised and will be published shortly.

Internal Claimants

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the Ministry of Defence (MOD) by members and former members of HM Forces and civilian employees since 2010 are as follows:

Employers Liabilty Claims (including Service personnel and civilian staff)

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£83.9 million	£62.0 million	£69.5 million	£58.5 million

The vast majority of clinical negligence claims are brought by current or former members of HM Armed Forces but a small number will relate to their dependants treated in MOD medical facilities. The amounts paid in compensation, including claimants’ legal costs, for these claims since 2010 are as follows:

Clinical Negligence Claims

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£17.0 million	£6.7 million	£7.1 million	£5.8 million

External Claimants

Public Liability Claims

The amounts paid in compensation, including claimants’ legal costs, for public liability claims brought against the MOD by third parties, including civilians both in the UK and overseas, relating to personal injury or property damage since 2010 are as follows:

FY 2010-11	2011-12	2012-13	2013-14
£5.4 million	£10.0 million	£25.0 million	£11.1 million

Third Party Motor Claims in UK

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the MOD by third parties involved in collisions with MOD-operated vehicles since 2010 are as follows:

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£5.6 million	£6.7 million	£4.8 million	£5.0 million

Area Claims Offices

The amounts paid in compensation, including claimants’ legal costs, for claims brought against the MOD by third parties that are managed by the MODs regional Area Claims Offices since 2010 are as follows:

FY 2010-11	FY 2011-12	FY 2012-13	FY 2013-14
£3.0 million	£1.8 million	£1.7 million	£1.5 million

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-09.

To ask the Secretary of State for Energy and Climate Change, what plans her Department has to ensure that the smart meter roll-out is used as an opportunity to engage with householders on the issue of carbon monoxide safety.

Andrea Leadsom

Energy suppliers are responsible for installing smart meters in their domestic customers’ premises. It is, a condition of their licence that energy suppliers must comply with the Smart Meter Installation Code of Practice, which is regulated by Ofgem:

http://www.smicop.co.uk/SitePages/Home.aspx

The Code states that the installer should inform the customer about the dangers of carbon monoxide (CO) and the need to regularly have all gas appliances serviced and checked by a Gas Safe Registered engineer.

“

The below Parliamentary question was asked by Andrew Gwynne on 2016-02-24.

To ask the Secretary of State for Health, how much of the £390 million funding referred to in paragraph 0.5 of his Department’s paper, Infected blood: reform of financial and other support, published in January 2016, was spent in each year to date; and what the average spend per recipient in each such year was.

Jane Ellison

The Department only holds finance data for payments under the Schemes back to 2007. This information is provided below.

2014-15 £22,278,096

2013-14 £27,043,569

2012-13 £22,052,458

2011-12 £27,192,232

2010-11 £39,805,667

2009-10 £22,461,057

2008-09 £19,240,337

2007-08 £20,532,461

The figures above include the annual payments to those with HIV and hepatitis C stage 2, and the lump sum payments made on joining the scheme and progressing to hepatitis C stage 2. The fluctuation in amounts between the years reflects the variance in number of people newly coming forward or progressing to hepatitis C stage 2 in each year.

The payments to individuals included both discretionary and non-discretionary payments, data on which is only held by the trusts and funds. Therefore, the Department is unable to estimate the levels of individual payments.

The below Parliamentary question was asked by Andrew Gwynne on 2016-03-08.

To ask the Secretary of State for Communities and Local Government, with reference to the letter to the hon. Member for Denton and Reddish from the Minister for Local Growth and the Northern Powerhouse of 18 February 2016, on accountability of combined authorities, if he will introduce call-in procedures for individual constituent district councils to scrutinise the decisions of combined authorities.

James Wharton

The scrutiny requirements for combined authorities are set out in Schedule 5A to the Local Democracy, Economic Development and Construction Act 2009, as inserted by the Cities and Local Government Devolution Act 2016, which provide that overview and scrutiny committees of combined authorities have powers to call in decisions and to involve other persons in their work. Schedule 5A also provides for secondary legislation which must ensure that the majority of members of an overview and scrutiny committee will be members of the combined authority’s constituent councils and that at least one member of an audit committee is an independent person. The scrutiny requirements of the Local Government Act 2000 do not apply to combined authorities.

The below Parliamentary question was asked by Andrew Gwynne on 2016-03-15.

To ask the Secretary of State for Health, what assessment his Department has made of the performance of the current data collection infrastructure and its capability to collect real world data in the way outlined in NHS England’s plans for a new Cancer Drugs Fund; and if he will make a statement.

George Freeman

Public Health England’s (PHE) National Cancer Registration and Analysis Service is the only national patient-level data source that collects data including outcomes on the whole care pathway on all patients diagnosed with cancer in England. Data are collected from all National Health Service trusts include information on Systemic Anti-Cancer Therapy.

There is presently no agreement between NHS England and PHE to provide outcome information on patients receiving Cancer Drugs Fund (CDF) funded treatments, on a regular basis. However, PHE and NHS England are currently in discussion to establish a dedicated resource to provide routine and bespoke information and analysis, and this could include defined outcome analyses on the CDF.

The Accelerated Access Review (AAR) is also looking at ways to better harness data to support the assessment, adoption and reimbursement of innovative treatments, and discussions are ongoing around the scope for aligning the revised CDF with the AAR recommendations.